Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a big mover this session as the company shares are trading 4.76% or 0.14 points lower from last closing price of $2.94, reaching $2.8 at last check. So what’s going on with ACHN shares anyway? The price has dropped in 2 of the last 5 days and is down -2.33% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -296,660 shares, and in total 308240 shares valued at $863072 were seen changing hands compared with 604900 shares valued at $1.778 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the ACHN stock is near its bottom.
Achillion Pharmaceuticals, Inc. (ACHN) shares have notched a 3-month decline of about -2.33%, but has still advanced 84.91% year to date. By comparison, the stock sank -1.67% over the past 12 months, while it slipped -0.34% over the 1 month. The company’s market cap is around $407.83M, with its short interest ratio standing at 6.22%.
In the current trading session for ACHN, the stock witnessed two major price actions, it rose to a high of $2.94 and was down as much as $2.795 at one point. The high recorded is very low when compared to their 52-week high which is $1.29. The 52-week high is now at -28.89 distance from current price. Their recent low of $3.98 represents a 119.38% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for ACHN is $4.17, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
ACHN‘s last price was up 0.45% as compared to the average trading price of 50 days recorded at $2.79 while enlarging the period to 200 trading days, the average closing price was $2.95. At present, there are 138.72 million in the total number of common shares owned by the public and among those 138.47 million shares have been available to trade. The percentage of shares being held by the company management was 0.15% while institutions stake was 83.5%. The company has generated negative returns on equity over the last 12 months (-25.2%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the ACHN stock, there is another set of technicals that should be looked into and considered. Its -1.2% decline from moving average of $2.83 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.97 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Achillion Pharmaceuticals, Inc. — 1 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 1 giving it a sell rating. Analysts arrived at a 12-month price target of $2.5 on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), which corresponds to 11.35% downside potential than its current market price of $2.8 and implies potential despite the recent drop in the price. However, their current target price has fallen from $2.5 a month ago and is down handily from the consensus target of $5 a quarter ago.
In the last five years, the EPS of the company has been roughly 4.1%. Though the percentage looks disappointing, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 17.58%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards ACHN stock. Mak Capital One LLC added position in the company after it grew 20.1% or 5,769,903 shares of its common stock. The hedge fund now owns 6,929,653 shares worth $19,403,028, SEC documents show. MetLife Investment Advisors LLC shored up assets in the stock as 45041.33 shares have been purchased, increasing its stake by 50% to 67,562 shares which are currently valued at $189,174. In addition, Metropolitan Life Insurance Co NY recently reported that it now owns 44,476 shares making a total of $124,533 based on the recent price. This refelects a change of 50% in their ownership.